GPCR/G protein


All GPCRs share a common seven trans-membrane structure. GPCRs are associated with heterotrimeric G-proteins which are GTP-binding proteins made of alpha, beta, and gamma subunits. When a ligand binds to GPCR, it activates the attached G-protein, the GDP is replaced with GTP. The activated G-protein then dissociates into an alpha and a beta-gamma complex which activates downstream signaling pathways. These intracellular signaling pathways include cAMP/PKA, calcium/NFAT, phospholipase C, protein tyrosine kinases, MAP kinases, PI-3-kinase, nitric oxide/cGMP, Rho, and JAK/STAT.
GPCRs are one of the most important therapeutic targets for various diseases, over 30% of all modern medicinal drugs target this family. Aberrant GPCR functions are involved in pathological conditions such as neurological, immunological and hormonal disorders. A large number of GPCRs have been identified, but whose ligands are not known, are classified as orphan receptors.
-
B5284 Motilin (human, porcine)Summary: Endogenous motilin receptor ligand -
B5287 Tabimorelin hemifumarateSummary: orally active ghrelin receptor (GHS-R1a) agonist -
B5296 Bombinakinin-GAPSummary: Bioactive bradykinin-related peptide -
B5297 Bombinakinin MSummary: Potent bradykinin receptor agonist -
B5298 ABT 702 dihydrochlorideTarget: Adenosine KinasesSummary: Adenosine kinase inhibitor -
B5299 Astressin 2BSummary: corticotropin-releasing factor receptor 2 (CRF2) antagonist -
B5302 DAPTASummary: Chemokine receptor 5 (CCR5) antagonist -
B5303 Apelin-36 (human)Summary: Endogenous APJ receptor agonist -
B5304 Apelin-36 (rat, mouse)Summary: Endogenous APJ receptor agonist -
B5306 Obestatin (rat)Summary: Endogenous peptide that suppresses food intake and body weight-gain

